View Document Preview and Link Document Date: 2015-02-19 08:17:29 Open Document File Size: 3,05 MB Share Result on Facebook
City Melbourne / Boston / / Company IgG / Cox / Atherogenesis Research Group Branch Application Pharma / / Country Germany / United States / / / Event Product Issues / / Facility Diabetes Institute / Freiburg University / Women’s Hospital / University of Freiburg / / / IndustryTerm treatment for atherosclerosis and other chronic inflammatory diseases / treatment of chronic inflammatory diseases / distinct binding site / / MedicalCondition inflammatory leukocytes / atherosclerosis / atherogenesis / chronic inflammatory diseases / inflammatory gene expression / inflammatory cell recruitment / Small Peptide Inhibitor Limits Inflammation / prevalent disease / chronic diseases / Inflammation / While inflammation / inflammatory diseases / inflammatory leukocyte recruitment / / MedicalTreatment immunization / / Organization Harvard Medical School / Freiburg University / African Union / 2Baker IDI Heart and Diabetes Institute / Women’s Hospital / University of Freiburg / Department of Cardiology / Freiburg University Medical Center / / / Position Responsible Scientist / / Product M-16 / Intraperitoneal injection / EC / / Technology gene expression / CD40L/Mac-1 interaction Technology / / URL www.atherogenesis.org / / SocialTag 
Treatment of Inflammation and Atherogenesis Therapeutic Targeting of CD40L/Mac-1 interaction Technology CD40L participates in chronic inflammatory diseases such as atherosclerosis. Through interaction with its classic